 |
| 삼성바이오로직스. (사진=삼성바이오로직스). |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics made an announcement on the 6th that it has signed a contract for consignment production (CMO) worth 3,819 billion won with Belgium-based global pharmaceutical company UCB. This contract is an increase contract for a $ 4,165 million (45.1 billion won) contract signed with UCB in 2017.
UCB has five types of epilepsy treatments, including blockbuster treatment 'Bim', and has been in partnership with Samsung BioLogics since 2017.
Samsung BioLogics explained that trust built based on the world's largest production capacity (604,000 liters), rapid response to emergency supply requests, and stable and high quality is leading to long-term partnerships.
Samsung BioLogics has 14 of the top 20 global big pharma companies as its customers, with cumulative orders reaching $12 billion since its foundation. The order amount last year was 3.5,009 trillion won.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
